Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
E

Exprivia SpA
MIL:XPR

Watchlist Manager
Exprivia SpA
MIL:XPR
Watchlist
Price: 1.52 EUR -12.14% Market Closed
Market Cap: €78.9m
Write Note Create Alert Ask AI
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

XPR Price Targets Summary
Exprivia SpA

There are no price targets for XPR.
XPR Lowest Forecast
Wall Street Target
Not Available
XPR Average Forecast
Wall Street Target
Not Available
XPR Highest Forecast
Wall Street Target
Not Available
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Exprivia SpA Competitors:
Price Targets
LIND
Lindblad Expeditions Holdings Inc
-10% Downside
LIND
Lindblad Expeditions Holdings Inc
-10% Downside

Revenue
Forecast

4% / Year
Past Growth
0% / Year
Estimated Growth
Estimates Accuracy
-4%
Average Miss
4% / Year
Past Growth
0% / Year
Estimated Growth
Estimates Accuracy
-4%
Average Miss

For the last 8 years the compound annual growth rate for Exprivia SpA's revenue is 4%. The projected CAGR for the next 1 year is 0%.

What are analyst estimates?

Operating Income
Forecast

8% / Year
Past Growth
4% / Year
Estimated Growth
Estimates Accuracy
6%
Average Beat
8% / Year
Past Growth
4% / Year
Estimated Growth
Estimates Accuracy
6%
Average Beat

For the last 8 years the compound annual growth rate for Exprivia SpA's operating income is 8%. The projected CAGR for the next 1 year is 4%.

What are analyst estimates?

Net Income
Forecast

14% / Year
Past Growth
4% / Year
Estimated Growth
Estimates Accuracy
8%
Average Beat
14% / Year
Past Growth
4% / Year
Estimated Growth
Estimates Accuracy
8%
Average Beat

For the last 8 years the compound annual growth rate for Exprivia SpA's net income is 14%. The projected CAGR for the next 1 year is 4%.

What are analyst estimates?

See Also

Summary
XPR intrinsic value, competitors valuation, and company profile.
DCF Valuation
XPR stock valuation using Discount Cash Flow valuation method.
Relative Valuation
XPR stock valuation using valuation multiples.
Wall Street Estimates
XPR price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
XPR stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is XPR's stock price target?
Not Available

XPR doesn't have any price targets made by Wall Street professionals.

What is Exprivia SpA's Revenue forecast?
Projected CAGR
0%

For the last 8 years the compound annual growth rate for Exprivia SpA's revenue is 4%. The projected CAGR for the next 1 year is 0%.

What is Exprivia SpA's Operating Income forecast?
Projected CAGR
4%

For the last 8 years the compound annual growth rate for Exprivia SpA's operating income is 8%. The projected CAGR for the next 1 year is 4%.

What is Exprivia SpA's Net Income forecast?
Projected CAGR
4%

For the last 8 years the compound annual growth rate for Exprivia SpA's net income is 14%. The projected CAGR for the next 1 year is 4%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 316,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.